Tacere Inks Deal With Oncolys BioPharma For RNAi Candidate
This article was originally published in PharmAsia News
Tacere Therapeutics has entered into a strategic alliance with Tokyo-based Oncolys BioPharma to develop its lead RNA interference-based candidate for treatment of hepatitis C, the companies announced June 21
You may also be interested in...
Deal comes on the heels of September agreement for potential RNAi therapy for macular degeneration.
Alnylam predicts companies will come knocking on its door to license its intellectual property in the field.
Merck continues acquisition spurt with purchase of San Francisco biotech.